“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...

It could also play a role in reducing the risk of dementia.We asked the experts. Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 ... The reduction in food preoccupation ...

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

Ozempic and Wegovy have the same active ingredient, semaglutide, in different doses, and mimic the hormone glucagon-like peptide-1. Released by the gut after eating, GLP-1 travels through the ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...